about
Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in micePharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects oInsight into SUCNR1 (GPR91) structure and function.New developments on thromboxane modulators.Progress in the field of GPIIb/IIIa antagonists.Identification and pharmacological characterization of succinate receptor agonists.Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis.Activation of the Orphan G Protein-Coupled Receptor GPR27 by Surrogate Ligands Promotes β-Arrestin 2 Recruitment.From the design to the clinical application of thromboxane modulators.Coxibs and cardiovascular side-effects: from light to shadow.Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials.Role of HCA₂ (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin.Human herpesvirus 8-encoded chemokine vCCL2/vMIP-II is an agonist of the atypical chemokine receptor ACKR3/CXCR7.Chemokine neutralization as an innovative therapeutic strategy for atopic dermatitis.Synthesis and pharmacological evaluation of 2-aryloxy/arylamino-5-cyanobenzenesulfonylureas as novel thromboxane A₂ receptor antagonists.Deorphanization of GPR109B as a receptor for the beta-oxidation intermediate 3-OH-octanoic acid and its role in the regulation of lipolysis.Design, synthesis, and SAR study of a series of N-alkyl-N'-[2-(aryloxy)-5-nitrobenzenesulfonyl]ureas and -cyanoguanidine as selective antagonists of the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor.Forskolin-free cAMP assay for Gi-coupled receptors.An autocrine lactate loop mediates insulin-dependent inhibition of lipolysis through GPR81.Heterologously expressed formyl peptide receptor 2 (FPR2/ALX) does not respond to lipoxin A₄.Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism.GPCRs in immunity: Atypical receptors and novel concepts.Pharmacological evaluation of both enantiomers of (R,S)-BM-591 as thromboxane A2 receptor antagonists and thromboxane synthase inhibitors.In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.Effects of dobutamine on left ventriculoarterial coupling and mechanical efficiency in acutely ischemic pigs.Characterization of an original model of myocardial infarction provoked by coronary artery thrombosis induced by ferric chloride in pig.Effects of BM-573, a thromboxane A2 modulator on systemic hemodynamics perturbations induced by U-46619 in the pig.Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion.Different contribution of chemokine N-terminal features attest a different ligand binding mode and a bias towards activation of the atypical chemokine receptor ACKR3/CXCR7 compared to CXCR4 and CXCR3.7-Phenoxy-Substituted 3,4-Dihydro-2H-1,2,4-benzothiadiazine 1,1-Dioxides as Positive Allosteric Modulators of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptors with Nanomolar Potency.Cardiovascular haemodynamics and ventriculo-arterial coupling in an acute pig model of coronary ischaemia-reperfusion.The G Protein-Coupled Receptors deorphanization landscape.Therapeutic applications of prostaglandins and thromboxane A2 inhibitors in abdominal aortic aneurysms.Partial filling affinity capillary electrophoresis as a useful tool for fragment-based drug discovery: A proof of concept on thrombin.Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists.The causes and consequences of pituitary gigantismBM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthaseBM-520, an original TXA2 modulator, inhibits the action of thromboxane A2 and 8-iso-prostaglandin F2alphain vitro and in vivo on human and rodent platelets, and aortic vascular smooth muscles from rodentsSynthesis and pharmacological evaluation of novel nitrobenzenic thromboxane modulators as antiplatelet agents acting on both the alpha and beta isoforms of the human thromboxane receptorEnhancing Action of Positive Allosteric Modulators through the Design of Dimeric Compounds
P50
Q24600864-0A8CE344-31FB-4F0F-8467-ADEBC485E810Q28166913-920F1064-2561-4DBE-AF6C-80B3A2E1CA8BQ34510713-840E93F9-5B00-4913-B5A0-BC00BE07F399Q35848224-5487E43B-7449-4D11-8C4A-1E0044F07659Q35867379-C8A27F82-606F-416F-A4D2-12D76A38C2D4Q36270614-AC40066A-7C55-4398-837E-3C9F9B486D1CQ36294176-DB0EEB0B-5B63-4098-8036-9F9C5143F806Q36313483-80DF5FC9-AF99-4147-BFB3-9C826FE64506Q36419627-25AB173B-4D91-4C12-9DE6-9BC12F8F7348Q36419642-0F33D1B0-0B9D-4526-A206-29E237422FC6Q37937990-612C1BF1-B6CF-45C0-AC08-9B62277D5323Q38022441-FD4B6C65-DD2E-483F-8BBA-D511BF457895Q38767597-47288A91-ABAA-498F-A0F4-06C9148A16B3Q39036663-0BBCA4D6-583B-4B39-B928-7CB401548ADAQ39149656-464D2C09-666B-435F-A9E4-51A0B07F7EC5Q39832093-3986F6A7-8B3D-44E7-ABB1-3DD2EB44768DQ40107212-9AB831CB-49B8-493A-BD6B-2DCF80AD3D58Q42482601-8393E283-A664-44C0-8831-0F23613A82F2Q43106856-0E57119F-F1F1-4528-840B-D7A3A6D87575Q44050421-A59969A6-CD83-4712-9053-5475C8B8C745Q44879627-CD25C1B7-2A72-47BF-953B-4699361B425CQ45038072-6AEA8C9D-845A-4FA8-BB68-A2F02574D06EQ45160197-CFBC988A-9AD8-4C43-A5C5-8653275A968EQ45207449-211C87B8-BE92-4E83-A6B3-EED8FB0CF4A0Q45226973-31CCCC0D-A3B9-4624-A50A-FF70A3FAA908Q46669223-BDD32671-7A0C-4D89-8B2B-BD8D40750BFFQ46816500-7198ADAA-616E-40F9-8686-E405C92850ECQ46975192-45D34178-2A33-45B8-85FC-855B9432D39FQ47260364-D7BF50B4-7411-42F7-9275-F487CA58F1B5Q48095397-966D8B07-207F-4968-9218-780A2B5F1105Q49168522-352D8F70-6E7C-4C42-A642-D0DA14481A91Q49898083-33F76CAC-BB1D-4818-BB18-0A9795E7DC52Q50128305-410EF4DB-A8CB-4D35-832E-A541878E2E8FQ52534236-2CE7E014-E363-4000-A2A0-81581CCDAECBQ52689477-852BB2BA-A364-4011-ADF0-1B81E400EA94Q58561293-9C730BAD-6EF2-4B4E-A457-E7071A606E96Q61596050-32DAD03D-E81F-4853-B52D-1293587B5C94Q80649879-12A89794-0E05-41DF-B55C-C3D9E16C82CDQ83943407-81C37F46-DB10-44C8-A35C-1200F42A375AQ88725557-805712E2-5DFD-49CF-B3FC-B415158C521B
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Julien Hanson
@ast
Julien Hanson
@en
Julien Hanson
@es
Julien Hanson
@nl
Julien Hanson
@sl
type
label
Julien Hanson
@ast
Julien Hanson
@en
Julien Hanson
@es
Julien Hanson
@nl
Julien Hanson
@sl
prefLabel
Julien Hanson
@ast
Julien Hanson
@en
Julien Hanson
@es
Julien Hanson
@nl
Julien Hanson
@sl
P106
P1153
7402747497
P21
P214
58153288323632652506
P31
P496
0000-0001-7063-7590